The recent success of gene therapy approaches for inherited retinal dystrophies highlights the potential to achieve improved outcomes in these patient populations by targeting the specific underlying genetic defect.28, 29 Large proteins such as CEP290, however, are not deliverable through current AAV gene therapy vectors30 and require smaller fragments to be used.31 The gene discussed is CEP290; the disease is Retinal dystrophy.